EN PL
PRACA PRZEGLĄDOWA
Zastosowanie diklofenaku w leczeniu bólu u pacjentów z chorobami reumatycznymi
 
Więcej
Ukryj
 
Data nadesłania: 22-05-2018
 
 
Data ostatniej rewizji: 20-06-2018
 
 
Data akceptacji: 25-06-2018
 
 
Data publikacji online: 30-06-2018
 
 
Data publikacji: 30-06-2018
 
 
Reumatologia 2018;56(3):174-183
 
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Diclofenac, a phenylacetic acid derivative, is a drug demonstrating high efficacy after oral administration in the treatment of pain and physical disability in rheumatic diseases. In view of the adverse effects associated with using diclofenac, it is necessary to consider all known drug safety information before the drug is selected for therapy and the dosage regimen is set for individual patients. Selecting an oral dosage form with specific properties determined by excipients is a method to improve the availability of the drug substance and, at the same time, minimize adverse drug reactions. An alternative to tablet or capsule dosage forms is diclofenac application to the skin. The proven efficacy of this method is further improved through the use of transdermal penetration enhancers and vehicle ingredients which provide dosage forms with specific physical properties.
 
REFERENCJE (57)
1.
Niedziałek D, Tłustochowicz W. Leczenie bólu w chorobach reumatycznych. Post Nauk Med 2012; 25: 109-114.
 
2.
Pereira-Leite C, Nunes C, Reis S. Interaction of nonsteroidal anti-inflammatory drug with membranes: in vitro assessment and relevance for their biological actions. Prog Lipid Res 2013; 52: 571-584.
 
3.
Międzyborski R. Kierunki poszukiwań i zastosowanie niesteroidowych leków przeciwzapalnych. Postepy Hig Med Dosw 2004; 58: 438-448.
 
4.
Rupiński R. Diklofenak – sprawdzony lek w leczeniu bólu w chorobach reumatycznych. Czy powinniśmy się go obawiać? Świat Med Farm 2017; 4: 94-100.
 
5.
Rajtar-Cynke G. Farmakologia. Czelej, Lublin 2015.
 
6.
Costa BR, Reichenbach S, Keller N, et al. Effectiveness of nonsteroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2017; 390: e21-e33.
 
7.
Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. Curr Med Res Opin 2012; 28: 163-178.
 
8.
Patnaik KP, Das P, Hota S, et al. Comparative safety and cost effective analysis between aceclofenac, lornoxicam and diclofenac in patients of musculoskeletal disorder. Int J Pharm Sci Res 2012; 3: 3407-3411.
 
9.
Supranowicz P. Ocena przydatności analogowej skali wizualnej (VAS) do mierzenia postawy młodzieży wobec zachowań szkodliwych dla zdrowia. Przegl Epidemiol 2003; 57: 541-551.
 
10.
Henrotin Y, De Leval X, Mathy-Hartet M, et al. In vitro effect of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res 2001; 50: 391-399.
 
11.
Hinz B, Rau T, Auge D, et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 225-235.
 
12.
Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolitic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Therapeut 1999; 289: 676-681.
 
13.
Kowalski ML, Makowska JS, Blanca M. Hypersensivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management. Allergy 2011; 66: 818-829.
 
14.
Lisowska B, Rell-Bakalarska M, Rutkowska-Sak L. Niesteroidowe leki przeciwzapalne – blaski i cienie. Reumatologia 2006; 44: 106-111.
 
15.
Tatarkiewicz J. Farmakoterapia bólu: wybrane zagadnienia. Część I. Farm Pol 2004; 60: 1001-1006.
 
16.
Zaremba M., Staniszewska A, Niewada M. Niesteroidowe leki przeciwzapalne – fakty, mity i kontrowersje dotyczące ryzyka sercowo-naczyniowego oraz ryzyka powikłań ze strony przewodu pokarmowego. Chor Serca Naczyń 2012; 9: 119-136.
 
17.
Wełnicki M, Mamcarz A. Stosowanie niesterydowych leków przeciwzapalnych u pacjentów kardiologicznych – aktualny stan wiedzy. Kardiol Prakt 2012; 6: 33-37.
 
18.
Kasztelan-Szczerbińska B, Słomka M, Celiński K, et al. Non-steroidal anti-inflammatory drugs – potential risk and benefits in the gastrointestinal tract distal to the ligament of Treitz. Przegl Gastroenterol 2010; 5: 145-150.
 
19.
Sriuttha P, Sirichanchuen,B, Permsuwan U. Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials. Int J Hepatol 2018; 5253623, 13 pages. https://doi.org/10.1155/2018/5....
 
20.
Rubenstein JH, Laine L. Systematic review: The hepatotoxicity of non-steroidalanti-inflammatory drugs. Aliment Pharmacol Ther 2004; 20: 373-380.
 
21.
Kellner HL, Li Ch, Essex MN. Celecoxib and diclofenac plus omeprazole are similarly effective in the treatment of arthritis in patients at high GI risk in the CONDOR trial. Open Rheumatol J 2013; 7: 96-100.
 
22.
Chan FKL, Lanas A, Scheiman J. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR); a randomised trial. Lancet 2018; 9736: 173-179.
 
23.
Reguła J. Wyniki badania Condor – porównanie skuteczności celekoksybu z diklofenakiem w skojarzeniu z omeprazolem. Med Dypl 2010; 19: 20.
 
24.
Wallace JL, Denou E, Vong L, Ongini E. Proton pump inhibitors and low-dose aspirin markedly exacebrate NSAID-induced small intestinal injury: link to dysbiosis? Gastroenterology 2011; 140: 68-87.
 
25.
Święcicki A, Antonienko A. The peculiarities of pathogenesis of NSAID-induced gastrointestinal injuries and current prevention strategies. Reumatologia 2014; 52: 155-159.
 
26.
Bolten WW, Krüger K, Reiter-Niesert S, Stichtenoth DO, Kommission Pharmakotherapie der DGRh. DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain. Z Rheumatol 2016; 75: 103-116.
 
27.
Rell K. Ryzyko powikłań sercowo-naczyniowych podczas leczenia NLPZ – komentarz do dwóch badań. Forum Med Rodz 2014; 8: 292-297.
 
28.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-anaysis. BMJ 2011; 342: c7086.
 
29.
Bhala N, Emberson J, Merhi A, et al. Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-779.
 
30.
McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098.
 
31.
Rell K. Wybrane aspekty bezpieczeństwa leczenia NLPZ. Pediatr Med Rodz 2011; 7: 41-48.
 
32.
Samborski W, Filipiak KJ, Kaczmarczyk J, et al. Niesteroidowe leki przeciwzapalne a powikłania sercowo-naczyniowe i gastroenterologiczne. Chor Serca Naczyń 2016; 13: 257-264.
 
33.
Ungprasert P, Cheungpasitporn W, Crowson CS, et al. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015; 26: 285-291.
 
34.
Zhang X, Donnan PT, Bell S, et al. Non-steroidal anti inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 2017; 18: 256.
 
35.
Joshi S, Rapoport AM. Diclofenac potassium for oral solution (CAMBIA®) in the acute management of a migraine attack: clinical evidence and practical experience. Ther Adv Neurol Disord 2017;10: 217-226.
 
36.
Ali H, Shoaib MH, Zafar F, et al. Pharmacokinetic and bioequivalence studies of immediate release diclofenac potassium tablets (50 mg) in healthy volunteers. Pak J Pharm Sci 2016; 29: 1671-1679.
 
37.
Amin ML, Jesmeen T, Sutradhar KB, et al. Development and in vitro evaluation of diclofenac sodium loaded mucoadhesive microsphere with natural gum for sustained delivery. Curr Drug Deliv 2013; 10: 765-770.
 
38.
Al-Hanbali OA, Hamed R, Arafat M, et al. Formulation and evaluation of diclofenac controlled release matrix tablets made of HPMC and Poloxamer 188 polymer: An assessment on mechanism of drug release. Pak J Pharm Sci 2018; 31(Suppl. 1): 345-351.
 
39.
Shahiwala A, Zarar A. Pharmaceutical product lead optimization for better in vivo bioequivalence performance: A case study of diclofenac sodium extended release matrix tablets. Curr Drug Deliv 2018; 15; 705-715.
 
40.
Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical topical NSAIDs in rheumatic diseases: a comparison. Drugs 2000; 60: 555-574.
 
41.
Sznitowska M. Farmacja stosowana. Technologia postaci leku. Wyd. Lekarskie PZWL, Warszawa 2017.
 
42.
Dehghanyar P, Mayer BX, Namiranian K, et al. Topical skin penetration of diclofenac after single- and multiple-dose application. Int J Clin Pharmacol Ther 2004; 42: 353-359.
 
43.
Rainsford KD, Kean WF, Ehrlich GE. Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008; 24: 2967-2992.
 
44.
Bookman AAM, Williams KSA, Shainhouse JZ. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: A randomized controlled trial. CMAJ 2004; 171: 333-338.
 
45.
Kigasawa K, Kajimoto K. Watanabe M, et al. In vivo transdermal delivery of diclofenac by ion-exchange iontophoresis with geraniol. Biol Pharm Bull 2009; 32: 684-687.
 
46.
Efe T, Sagnak E, Roessler PP, et al. Penetration of topical diclofenac sodium 4% spray gel intro the synovial fluid of the knee: a randomised clinical trial. Knee Surg Sports Traumatol Arthrosc 2014; 22: 345-350.
 
47.
Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% vs oral diclofenac sodium in healthy volunteers. J Clin Pharmacol 2010; 50: 50-61.
 
48.
Brunner M, Dehghanyar P, Seigfried B, et al. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol 2005; 60: 573-577.
 
49.
Miyatake S, Ichiyama H, Kondo E, et al. Randomized clinical comparisons of diclofenac concentration in the soft tissues and blood plasma between topical and oral applications. Br J Clin Pharmacol 2009; 67: 125-129.
 
50.
Chen X, Gallar J, Belmonte C. Reduction by antiinflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation. Invest Ophthalmol Vis Sci 1997; 38: 1944-1953.
 
51.
Dong XD, Svensson P, Cairns BE. The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism. Pain 2009; 147: 36-45.
 
52.
Yarishkin OV, Hwang EM, Kim D, et al. Diclofenac, a non-steroidal anti-inflammatory drug, inhibits L-type Ca channels in neonatal rat ventricular cardiomyocytes. Korean J Physiol Pharmacol 2009; 13: 437-442.
 
53.
Derry S, Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronić pain in adults – an overview of Cochrane Reviews. Cochrane Database Syst Rev 2017; 5: CD008609.
 
54.
Białecka M, Machoy-Mokrzyńska A, Bojko A. Znaczenie wskaźnika NNT (number needed to treat) podczas leczenia bólu lekami z grupy niesteroidowych leków przeciwzapalnych (NLPZ). Terapia 2013; 21: 109-113.
 
55.
Kwiatkowska B. Skuteczność ketoprofenu stosowanego miejscowo w postaci żelu. Pediatr Med Rodz 2013; 9: 60-63.
 
56.
Baraf HS, Gloth FM, Barthel HR, et al. Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from Tyree randomized, double-blind paralel-group, placebo controlled, multicentre trials. The Phys Sportsmed 2010; 38: 19-28.
 
57.
Hsieh LF, Hong CZ, Chern SH, et al. Efficacy and side effects of diclofenac patch in treatment of patients with myofascial pain syndrome of the upper trapezius. J Pain Symptom Manage 2010; 39: 116-125.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top